Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 2,085 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Intermittent Claudication
Interventions: Cilostazol 100 mg, PMR 200 mg; Drug
Lead sponsor: Genovate Biotechnology Co., Ltd.,; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Povetacicept; Drug
Lead sponsor: Alpine Immune Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Imatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Schizophrenia
Interventions: Pimavanserin; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 995 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more

Conditions: Hepatitis B
Interventions: JNJ-56136379, Placebo, NA (ETV or TDF); Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Bakersfield, California • Orlando, Florida • Chicago, Illinois + 4 more

Conditions: Healthy Volunteers
Interventions: CANA/MET XR FDC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Major Depressive Disorder
Interventions: BHV-7000; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 66
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Alzheimer's Disease
Interventions: Donepezil; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 45 Years to 91 Years
Enrollment: 915 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Santa Ana, California

Conditions: Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Intestinal Diseases, Colonic Diseases, Autoimmune Disease, Abdominal Pain
Interventions: KHK4083, Placebo; Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: NNRTI, FTC/TDF, Stribild; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 39
States / cities: Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more

Conditions: Diabetes Mellitus, Type 1
Interventions: insulin icodec, insulin degludec, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 42
States / cities: Concord, California • Escondido, California • Fresno, California + 36 more

Conditions: Ulcerative Colitis
Interventions: PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD, Placebo, PF-6826647 400 mg QD; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: Canoga Park, California • Inglewood, California • Newport Beach, California + 12 more

Conditions: Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Interventions: Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more

Conditions: Major Depressive Disorder
Interventions: Combination Product: BCI-024 + BCI-049; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more

Conditions: Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Interventions: fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple System Atrophy (MSA)
Interventions: ONO-2808, Placebo; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 30
States / cities: Fountain Valley, California • Los Angeles, California • Palo Alto, California + 23 more

Conditions: Graft vs Host Disease, Kidney Transplantation
Interventions: Sirolimus (RAPAMUNE); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 10 more

Conditions: Carcinoma, Renal Cell
Interventions: Orellanine; Drug
Lead sponsor: Oncorena AB; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Orange, California • Palo Alto, California • San Francisco, California + 3 more

Conditions: Systemic Lupus Erythematosus
Interventions: Dapirolizumab pegol; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 16 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 34
States / cities: Birmingham, Alabama • Avondale, Arizona • Glendale, Arizona + 30 more

Conditions: CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
Interventions: CTAP101; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Kansas City, Missouri • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Ralinepag; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 18
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 15 more

Conditions: Migraine
Interventions: Eptinezumab; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 20
States / cities: New Haven, Connecticut • Stamford, Connecticut • Gainesville, Florida + 17 more

Conditions: Canavan Disease
Interventions: rAAV-Olig001-ASPA, Levetiracetam, Prednisone; Drug
Lead sponsor: Myrtelle Inc.; Industry
Eligibility: 3 Months to 60 Months
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Amyloidosis; Systemic
Interventions: AT02; Drug
Lead sponsor: Attralus, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Kansas City, Kansas • Cleveland, Ohio • Portland, Oregon + 1 more

Search by objective public record fields.

Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

A Long-term Extension Study of Ustekinumab in Pediatric Participants

Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

A Study of AT-02 in Subjects With Systemic Amyloidosis.